Dr. Salari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit St., GRB-1109A
Boston, MA 02114
Summary
- Dr. Keyan Salari is a urologic oncologist in Boston, MA and is affiliated with Massachusetts General Hospital and Harvard Medical School. He received his medical degree from Stanford University School of Medicine and trained at Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center. He has been in practice 7 years. He is experienced in urology, oncology, and cancer genomics.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2018 - 2019
- Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2014 - 2018
- Massachusetts General HospitalInternship, Surgery, 2012 - 2013
- Stanford University School of MedicineClass of 2012, M.D.
- Stanford UniversityPh.D., Genetics, 2010
- University of California, BerkeleyB.A., Molecular and Cell Biology, 2004
Certifications & Licensure
- MA State Medical License 2012 - 2026
- ME State Medical License 2020 - 2026
- RI State Medical License 2021 - 2026
- NH State Medical License 2021 - 2025
- NY State Medical License 2017 - 2019
- American Board of Urology Urology
Publications & Presentations
PubMed
- 137 citationsBiologically informed deep neural network for prostate cancer discovery.Haitham Elmarakeby, Justin H. Hwang, Rand Arafeh, Jett Crowdis, Sydney Gang
Nature. 2021-09-22 - 182 citationsPopulation stratification confounds genetic association studies among LatinosShweta Choudhry, Natasha E. Coyle, Hua Tang, Keyan Salari, Denise L. Lind
Human Genetics. 2006-01-01 - 169 citationsGenomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancerKevin A. Kwei, Young Ho Kim, Luc Girard, Jessica Kao, Manuela Pacyna-Gengelbach
Oncogene. 2008-06-05
Journal Articles
- Detection of Pathogenic Variants with Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients with Prostate Cancer and MelanomaKeyan Salari, MD, JAMA
Press Mentions
- Genomic Urine Test Detects Bladder Cancer from DNA up to 12 Years Before Clinical Signs and Symptoms AppearMay 1st, 2023
- Role of HRD in Early-Stage Prostate CancerMay 31st, 2022
- Metabolic Syndrome Post-Prostatectomy Ups Prostate Cancer Death RiskSeptember 12th, 2021
- Join now to see all
Professional Memberships
- American Urological AssociationMember
Other Languages
- Spanish, Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: